{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"100.0"},{"groupId":"OG002","value":"100.0"}]}],"title":"Day 5 (total=1, 4, 6)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"100.0"},{"groupId":"OG002","value":"83.3"}]}],"title":"Day 8 (total = 1, 4, 6)"},{"categories":[{"measurements":[{"comment":"no patients with positive reading (greater than two fold increased when compared to baseline) at this time point in the dose group.","groupId":"OG000","value":"NA"},{"groupId":"OG001","value":"50.0"},{"groupId":"OG002","value":"60.0"}]}],"title":"Day 10 (total=1, 4, 5)"},{"categories":[{"measurements":[{"comment":"No patients were analyzed for this arm.","groupId":"OG000","value":"NA"},{"groupId":"OG001","value":"33.3"},{"groupId":"OG002","value":"40.0"}]}],"title":"Day 12 (Total=0, 3, 5)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"33.3"},{"groupId":"OG002","value":"0"}]}],"title":"Day 15 (Total=1, 3, 5)"},{"categories":[{"measurements":[{"comment":"No patients were analyzed for this arm.","groupId":"OG000","value":"NA"},{"groupId":"OG001","value":"50.0"},{"comment":"No patients were analyzed for this arm.","groupId":"OG002","value":"NA"}]}],"title":"End of Study (Total=0, 2, 0)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"15"}],"units":"Participants"}],"groups":[{"description":"Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF)","id":"OG000","title":"Arm 2, Group Y (30 mg)"},{"description":"Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF)","id":"OG001","title":"Arm 2, Group Y (45 mg)"},{"description":"Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF)","id":"OG002","title":"Arm 2, Group Y (60 mg)"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set","reportingStatus":"POSTED","timeFrame":"Days 5, 8, 10, 12, 15, End of study (up to 3.5 years)","title":"Percentage of Participants With Histone Acetylation Induction in Peripheral Blood in Arm 2 (MWF Every Other Week), Group Y","type":"SECONDARY","unitOfMeasure":"Percentages of participants"}